An *in vivo* evaluation of the potential of $^{188}$Re-PEI-MP for therapy of bladder carcinoma and $^{99m}$Tc-PEI-MP for diagnosis and follow up

S Ferreira$^{1,2,3}$, M Laranjo$^4$, AM Abrantes$^4$, A Brito$^1$, L Metello$^3$, J Zeevart$^5$, W Louw$^5$, I Dormehl$^6$, MF Botelho$^4$

$^1$Biophysics Unit, IBILI, Faculty of Medicine, University of Coimbra, Coimbra, Portugal

$^2$School of Sciences, University of Minho, Braga, Portugal

$^3$Nuclear Medicine Course, High Institute of Allied Health Technologies of Porto’s Polytechnic Institute, Porto, Portugal

$^4$Biophysics Unit, IBILI, CIMAGO, Faculty of Medicine, University of Coimbra, Coimbra, Portugal

$^5$Radiochemistry Department, NECSA, Pretoria, South Africa

$^6$Department of Internal Medicine, University of Pretoria, South Africa

**Introduction:** The development of water-soluble polymers such as PEI-MP (polyethyleneimine, functionalised with methylphosphonate groups) that might be labeled with $^{188}$Re (emits of high energy beta particles) and $^{99m}$Tc are recent approaches, with a strong potential for metabolic radiotherapy and diagnosis, respectively. The aim of this study was to evaluate the efficacy of $^{188}$Re-PEI-MP as therapeutic agent for bladder carcinoma and $^{99m}$Tc-PEI-MP for its diagnosis and follow up.

**Material and Method:** Cytotoxicity of PEI-MP was investigated in bladder carcinoma cell line (CRL-1472) using the MTT test for different concentrations of PEI-MP (1 µM to 1000 µM) and incubation times (24h, 48h, 72h and 96h). Radiochemical purity of $^{188}$Re-PEI-MP and $^{99m}$Tc-PEI-MP was achieved using ascending microchromatography. The *in vivo* studies were performed after the approval by Ethics Committee of the Faculty of Medicine, University of Coimbra. It was used six groups of Balb/c nu/nu mice: four normal groups injected with Na$^{188}$ReO$_4$ (n=18), $^{188}$Re-PEI-MP (n=17), Na$^{99m}$TcO$_4$ (n=10) and $^{99m}$Tc-PEI-MP (n=10), respectively; two with bladder
carcinoma xenotransplants injected with Na\textsuperscript{188}ReO\textsubscript{4} (n=8) and 188\textsuperscript{Re}-PEI-MP (n=12), respectively. When tumor reached the appropriate volume, Na\textsuperscript{188}ReO\textsubscript{4}, 188\textsuperscript{Re}-PEI-MP, Na\textsuperscript{99m}TcO\textsubscript{4} or 99m\textsuperscript{Tc}-PEI-MP, were administered by an intravenous injection in the tail vein (22-37MBq), with the animal anesthetized and previously placed on the gamma camera detector. Immediately, a dynamic acquisition followed, with a 128x128 matrix for 10 min (20 frames, 30 seconds). Static images (2 min) were performed with a 256x256 matrix, where each of the six groups was divided into two groups, of which one was imaged at 120 minutes, and the other at 240 minutes. For biodistribution proposes, mice were euthanized 2 and 4 hours after injection and organ samples where weighted and counted in a well-counter to obtain percentage injected activity per gram of organ (%ID/g).

**Results and Discussion:** The MTT assay showed that PEI-MP is not cytotoxic. The radiochemical purity of 188\textsuperscript{Re}-PEI-MP and 99m\textsuperscript{Tc}-PEI-MP was ≥85%. Biodistribution results, with Na\textsuperscript{188}ReO\textsubscript{4} and Na\textsuperscript{99m}TcO\textsubscript{4}, showed a higher uptake by the thyroid, bladder and stomach, following a normal biodistribution. The biodistribution with 188\textsuperscript{Re}-PEI-MP and 99m\textsuperscript{Tc}-PEI-MP showed that the excretion of these complexes occurs primarily through the renal system, with a small fraction being eliminated by the hepatobiliary system. Tumor/muscle ratio for 188\textsuperscript{Re}-PEI-MP was greater than 1.5.

**Conclusions:** Given to its biodistribution and tumor/muscle ratio, 188\textsuperscript{Re}-PEI-MP seems to be promising in the treatment of bladder cancer. Following the same biodistribution as 188\textsuperscript{Re}-PEI-MP, 99m\textsuperscript{Tc}-PEI-MP seems to be optimal for diagnosis and follow up of therapy.

*It has been decided that it would not be shown the entire version of this document.*

*To obtain more informations:*

www.nucmedonline.net

cursomedicinanuclear@gmail.com